TY - JOUR
T1 - Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor
AU - Puls, Florian
AU - Carter, Jodi M.
AU - Pillay, Nischalan
AU - McCulloch, Thomas A.
AU - Sumathi, Vaiyapuri P.
AU - Rissler, Pehr
AU - Fagman, Henrik
AU - Hansson, Magnus
AU - Amary, Fernanda
AU - Tirabosco, Roberto
AU - Magnusson, Linda
AU - Nilsson, Jenny
AU - Flanagan, Adrienne M.
AU - Folpe, Andrew L.
AU - Mertens, Fredrik
N1 - Funding Information:
We are grateful for technical assistance of Anne Palin-Masreliez, Gülay Altiparmak and Jasminka Sirinova. Dr Puls is supported by grants from the Johan Jansson Foundation. Dr. Mertens is supported by grants from the Swedish Cancer Society (CAN2017/269) and Region Skåne. Dr Pillay is supported by a Cancer Research UK Clinician Scientist award (Award no: 18387). The study is also supported by the National Institute for Health Research, UCLH Biomedical Research Center, the UCL Experimental Cancer Center (AMF, NP), and the RNOH Biobank (AMF, RT).
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
PY - 2022/6
Y1 - 2022/6
N2 - Superficial CD34-positive fibroblastic tumor (SCD34FT) is a recently recognized soft tissue tumor that is considered to be of borderline malignancy. The pathogenesis of this tumor remains incompletely understood, but it has been suggested that SCD34FT overlaps with tumors showing fusions involving the PRDM10 gene. Previous analyses of PRDM10-rearranged tumors have demonstrated that they have a distinct gene expression profile, resulting in high expression of CADM3 (also known as SynCam3), which can be detected immunohistochemically. Here, we investigated a series (n = 43) of SCD34FT or PRDM10-rearranged tumors and potential mimics (n = 226) with regard to morphological, genetic, and immunohistochemical features. The results show that SCD34FT and PRDM10-rearranged tumor are morphologically indistinguishable; 41 of 43 tumors of both entities are CADM3-positive. Hence, we suggest that they constitute a single entity, preferably referred to as SCD34FT. Expression of CADM3 was only rarely seen in other soft tissue tumors, except in tumors with Schwann cell differentiation. Thus, IHC for CADM3, in combination with the characteristic morphological features, is a valuable adjunct in the diagnosis of SCD34FT.
AB - Superficial CD34-positive fibroblastic tumor (SCD34FT) is a recently recognized soft tissue tumor that is considered to be of borderline malignancy. The pathogenesis of this tumor remains incompletely understood, but it has been suggested that SCD34FT overlaps with tumors showing fusions involving the PRDM10 gene. Previous analyses of PRDM10-rearranged tumors have demonstrated that they have a distinct gene expression profile, resulting in high expression of CADM3 (also known as SynCam3), which can be detected immunohistochemically. Here, we investigated a series (n = 43) of SCD34FT or PRDM10-rearranged tumors and potential mimics (n = 226) with regard to morphological, genetic, and immunohistochemical features. The results show that SCD34FT and PRDM10-rearranged tumor are morphologically indistinguishable; 41 of 43 tumors of both entities are CADM3-positive. Hence, we suggest that they constitute a single entity, preferably referred to as SCD34FT. Expression of CADM3 was only rarely seen in other soft tissue tumors, except in tumors with Schwann cell differentiation. Thus, IHC for CADM3, in combination with the characteristic morphological features, is a valuable adjunct in the diagnosis of SCD34FT.
UR - http://www.scopus.com/inward/record.url?scp=85122084603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122084603&partnerID=8YFLogxK
U2 - 10.1038/s41379-021-00991-8
DO - 10.1038/s41379-021-00991-8
M3 - Article
C2 - 34969957
AN - SCOPUS:85122084603
SN - 0893-3952
VL - 35
SP - 767
EP - 776
JO - Modern Pathology
JF - Modern Pathology
IS - 6
ER -